Advertisement
ABBV vs REGN
Which Stock Would AI Choose? AbbVie (ABBV) vs. Regeneron (REGN) Stock Comparison
Key Takeaways
- ABBV shares have experienced recent volatility, with YTD returns around 3% and a 52-week range of $164.39 to $244.81, supported by positive Phase 3 data for SKYRIZI in Crohn's disease and Phase 1 results for obesity candidate ABBV-295.
- REGN shows steadier momentum, with YTD gains near 3% and a 52-week range of $476.49 to $821.11, bolstered by positive Phase 3 obesity data for licensed olatorepatide and ongoing Dupixent expansions.
- ABBV offers a higher market cap (~$388B vs. ~$79B for REGN) and attractive dividend yield (~3%), appealing to income-focused investors, while REGN's lower P/E (~18 vs. ABBV's ~93) suggests relative value.
- Both biotech giants benefit from strong pipelines in immunology and obesity, but ABBV emphasizes diversified immunology growth post-Humira, while REGN leverages collaborations like Dupixent for broader exposure.
- Analyst targets indicate upside: ABBV ~$249 (13% potential), REGN ~$873 (17% potential), reflecting optimism in recent catalysts.
Introduction
AbbVie (ABBV) and Regeneron (REGN) represent leading biopharmaceutical firms navigating competitive landscapes in immunology, oncology, and emerging obesity treatments. This stock comparison evaluates their recent market positioning, pipeline momentum, and relative performance amid sector volatility. Traders seeking short-term opportunities may focus on catalyst-driven moves, while long-term investors weigh stability, dividends, and growth potential. With both companies reporting positive clinical data in recent weeks, understanding their contrasts aids informed decisions on relative performance and market positioning in the biotech arena.
ABBV Overview and Recent Performance
AbbVie (ABBV), a research-driven biopharmaceutical leader, focuses on immunology, oncology, neuroscience, and aesthetics, with key products like Skyrizi, Rinvoq, and Botox driving revenue. Headquartered in North Chicago, it serves over 75 conditions globally through a pipeline of ~90 compounds. Recent market activity has seen ABBV shares trade around $220, within a 52-week range of $164 to $245, reflecting YTD gains of ~3% but recent weekly dips amid broader market pressures. Sentiment has been influenced by strong Q4 earnings, upbeat 2026 profit forecasts from immunology drugs offsetting Humira declines, and a $380M U.S. manufacturing expansion. Positive topline Phase 3 AFFIRM results for subcutaneous Skyrizi in Crohn's disease and Phase 1 data for obesity drug ABBV-295 (up to ~10% weight loss) have bolstered pipeline confidence, though high P/E (~93) and competition temper gains.
REGN Overview and Recent Performance
Regeneron (REGN), a biotechnology innovator based in Tarrytown, New York, discovers and commercializes medicines for eye diseases, cancer, allergies, and metabolic disorders, with flagship products like Eylea and Dupixent. Its pipeline targets serious unmet needs across multiple modalities. Shares recently hovered near $746, in a 52-week range of $476 to $821, with YTD returns ~3% and steadier recent momentum compared to peers. Performance reflects Q4 profit beats from Dupixent demand and positive Phase 3 obesity trial results for licensed olatorepatide (up to 19% weight loss in Chinese patients), signaling global Phase 3 initiation. Regulatory progress, including Dupixent expansions and Eylea manufacturing updates, supports sentiment, aided by a more attractive P/E (~18), despite competition in ophthalmology.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top-performing AI trading bots from its library of 351, optimized for current market conditions across stocks, ETFs, and crypto. These bots employ diverse AI/ML strategies, including trend-following, swing trading, hedging, and volatility plays, with timeframes from 5 minutes to 60 days. Standout stats include annualized returns up to +209%, win rates of 52-95%, profit factors to 25.8, and coverage of 1-25 tickers in sectors like semiconductors, energy, and aerospace. Neither ABBV nor REGN features prominently, but the platform's hundreds of bots trade thousands of tickers with varying styles and performances. Explore these curated tools to align with your strategy—visit Trending AI Robots for live insights and copy-trading options.
Head-to-Head Comparison
AbbVie (ABBV) and Regeneron (REGN) both thrive in immunology and obesity but differ in scale and approach. ABBV's diversified model (~$388B market cap) relies on mature blockbusters like Skyrizi/Rinvoq for steady growth post-Humira, contrasting REGN's (~$79B cap) biotech focus on innovative platforms and partnerships (e.g., Sanofi for Dupixent). Growth drivers include ABBV's aesthetics/oncology breadth versus REGN's eye disease and oncology depth. Recent momentum favors REGN's stability (lower beta implied by performance), while ABBV offers dividends. Risks: ABBV faces patent pressures; REGN, pipeline dependency. Sector exposure overlaps in biotech, but REGN edges on valuation; sentiment tilts to ABBV's yield for conservative plays.
Tickeron AI Verdict
Tickeron's AI leans toward REGN in the current environment, citing superior relative valuation (P/E ~18 vs. ~93), consistent trend stability, and high-upside obesity catalysts like olatorepatide amid sector tailwinds. While ABBV shows pipeline promise, its premium pricing and volatility suggest higher risk; REGN's positioning offers probabilistic edge for momentum traders, though both warrant monitoring for clinical readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and REGN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileREGN’s FA Score has 2 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- REGN’s TA Score: 3 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -2.44% price change this week, while REGN (@Biotechnology) price change was +1.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.10%. For the same industry, the average monthly price growth was +0.24%, and the average quarterly price growth was +6.99%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.57%. For the same industry, the average monthly price growth was +5.22%, and the average quarterly price growth was +13.90%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
REGN is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.10% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.57% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | REGN | ABBV / REGN | |
| Capitalization | 356B | 74.9B | 475% |
| EBITDA | 17.6B | 5.75B | 306% |
| Gain YTD | -10.343 | -7.271 | 142% |
| P/E Ratio | 98.80 | 17.45 | 566% |
| Revenue | 61.2B | 14.9B | 411% |
| Total Cash | N/A | 8.75B | - |
| Total Debt | 67.5B | 2.71B | 2,494% |
ABBV | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 16 | 77 | |
SMR RATING 1..100 | 1 | 58 | |
PRICE GROWTH RATING 1..100 | 60 | 57 | |
P/E GROWTH RATING 1..100 | 30 | 30 | |
SEASONALITY SCORE 1..100 | n/a | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (4) in the Biotechnology industry is in the same range as ABBV (24) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (77) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than REGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (58) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (57) in the Biotechnology industry is in the same range as ABBV (60) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to ABBV’s over the last 12 months.
REGN's P/E Growth Rating (30) in the Biotechnology industry is in the same range as ABBV (30) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | REGN | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 76% |
| Stochastic ODDS (%) | 4 days ago 52% | 4 days ago 71% |
| Momentum ODDS (%) | 4 days ago 61% | 4 days ago 58% |
| MACD ODDS (%) | 4 days ago 57% | 4 days ago 49% |
| TrendWeek ODDS (%) | 4 days ago 48% | 4 days ago 65% |
| TrendMonth ODDS (%) | 4 days ago 53% | 4 days ago 60% |
| Advances ODDS (%) | 12 days ago 57% | N/A |
| Declines ODDS (%) | 4 days ago 48% | 13 days ago 52% |
| BollingerBands ODDS (%) | 4 days ago 54% | 4 days ago 60% |
| Aroon ODDS (%) | 4 days ago 44% | 4 days ago 63% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VGT | 112.44 | 2.94 | +2.68% |
| Vanguard Information Technology ETF | |||
| EHY | 11.44 | 0.14 | +1.28% |
| Amplify Ethereum Max Income Covered Call ETF | |||
| LSGR | 45.55 | 0.48 | +1.06% |
| Natixis Loomis Sayles Focused Growth ETF | |||
| BNDC | 22.16 | 0.04 | +0.18% |
| FlexShares Core Select Bond ETF | |||
| GDOC | 31.66 | -0.14 | -0.43% |
| Goldman Sachs Future Health Care Eq ETF | |||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with SMMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +0.82% | ||
| SMMT - REGN | 43% Loosely correlated | +5.42% | ||
| ARQT - REGN | 39% Loosely correlated | +2.47% | ||
| IDYA - REGN | 35% Loosely correlated | +0.28% | ||
| GMAB - REGN | 34% Loosely correlated | -2.33% | ||
| INCY - REGN | 33% Poorly correlated | +0.81% | ||
More | ||||